Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants by Seini Moimoi | Feb 21, 2023 | Portfolio News
Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 by Seini Moimoi | Feb 16, 2023 | Portfolio News
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria by Seini Moimoi | Jan 30, 2023 | Portfolio News
Cohere Health Introduces Cohere Unify™ Intelligent Prior Authorization by Seini Moimoi | Jan 25, 2023 | Portfolio News
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD) by Seini Moimoi | Jan 11, 2023 | Portfolio News
Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine by Seini Moimoi | Jan 10, 2023 | Portfolio News
Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial Evaluating AVB-001 for the Treatment of Ovarian Cancer by Seini Moimoi | Jan 9, 2023 | Portfolio News
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) by Seini Moimoi | Jan 8, 2023 | Portfolio News
Nalu Medical, Inc., Announces Publication of Two Spinal Cord Stimulation Clinical Studies by Seini Moimoi | Jan 5, 2023 | Portfolio News
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults by Seini Moimoi | Jan 5, 2023 | Portfolio News
